Reuters logo
BRIEF-Human Stem Cells Institute to develop ischemia drug in U.S. and Canada
October 12, 2016 / 2:11 PM / a year ago

BRIEF-Human Stem Cells Institute to develop ischemia drug in U.S. and Canada

Oct 12 (Reuters) - Human Stem Cells Institute :

* Says it has licensed the exclusive U.S. and Canadian rights for Neovasculgen to ArtGen, Inc., a privately held biotechnology company located in Rockville, MD

* Neovasculgen is a first-in-class gene therapy drug that was approved in 2011 for human use in Russia for treatment of atherosclerotic Peripheral Arterial Disease, including Critical Limb Ischemia

* Says it will receive milestone payments, royalties and future equity participation rights in ArtGen

Source text: bit.ly/2dkojqw

Further company coverage:

Gdynia Newsroom

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below